Iterum Therapeutics PLC

ITRMF Healthcare Biotechnology

In the quarter to September 2025, revenue grew 110.8%, EPS grew 33.3% and free cash flow fell 179.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.00 0.00 NaN
Market cap
$1.6M
P/E
0.0×
Fwd P/E
−1.0×
Dividend yield
—
F-score
2/9
Altman Z
−26.27
Beneish M
22.81
Dividend safety
n/a
Sep '25 Jun '25 Mar '25 Dec '24 Older periods
ROE
285.48% 325.35% 518.47% 472.61%

+8 more TTM periods

ROA
(111.35%) (99.93%) (85.79%) (69.93%)
ROIC
(455.51%) (297.39%) (184.61%) 0.00%
Return on Tangible Assets
(368.57%) (256.98%) (227.85%) (343.84%)
Average Days of Receivables
177.74 — — 0.00
Free Cash Flow per Share
(0.43) (0.37) (0.49) (1.36)
Free Cash Flow
(19.53) (14.74) (16.75) (26.77)
Other line items

Show all line items

Columns are period end dates